消痔灵灌注治疗膀胱疼痛综合征/间质性膀胱炎  

Xiaozhiling Perfusion in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis

作　　者：朱旋[1] 范洁[1] 高文喜[1] 胡少炜[1] 曾令启[1] 张忠民[1] 

机构地区：[1]湖北省中医院泌尿外科(湖北省中医药研究院),武汉430061

出　　处：《中国中西医结合外科杂志》2017年第5期506-509,共4页Chinese Journal of Surgery of Integrated Traditional and Western Medicine

摘　　要：目的:观察消痔灵灌注治疗膀胱疼痛综合征/间质性膀胱炎(PBS/IC)的疗效及安全性。方法:选取39例PBS/IC患者,先行麻醉下膀胱水扩张术治疗1次,然后随机分为消痔灵灌注组(A组20例)和透明质酸钠(西施泰)灌注组(B组19例)。每周灌注1次,连续灌注4周改为每月1次,直到第6个月。分别于治疗前和治疗后第1、6个月监测每日排尿次数、最大排尿量、视觉模拟评分、O’Leary-Sant IC问卷表评分、生活质量评分以及不良反应情况。结果:膀胱灌注治疗1个月后A、B两组每日排尿次数(14.5±7.2、13.4±9.5)、最大排尿量(185.7±41.6、190.8±45.7)、视觉模拟评分(3.7±0.8、3.4±0.6)、O’Leary-Sant IC问卷评分(14.7±4.9、13.9±5.9)、生活质量评分(1.8±0.8、1.7±0.9),较治疗前均有明显改善(P<0.05)。膀胱灌注治疗6个月后A、B两组每日排尿次数(15.43±6.7、14.5±7.8)、最大排尿量(195.8±44.5、201.7±48.3)、视觉模拟评分(3.9±0.8、3.6±0.7)、O’Leary-Sant IC问卷评分(16.2±4.4、15.5±5.6)、生活质量评分(2.3±1.1、2.1±1.3),较治疗前均有明显改善(P<0.05)。A、B两组间相比较各指标改变程度的差异均无统计学意义(P>0.05)。A组出现膀胱刺激征7例、血尿4例;B组出现膀胱刺激征3例、血尿1例。结论:消痔灵膀胱灌注治疗PBS/IC安全、有效,其疗效等同于透明质酸钠。Objective To observe the efficacy and safety of Xiaozhiling perfusion in the treatment of pain- ful bladder syndrome/interstitial cystitis （PBS/IC）. Methods Thirty-nine patients with PBS/IC were selected. All patients were treated with endoscopic bladder dilation and then randomly divided into Xiaozhiling perfusion group （A group, n=20） and sodium hyaluronate （Cystistat） reperfusion group （B group, n=19）. Postoperative water perfusion was performed once per week, for four consecutive weeks, followed by once per month up to the sixth month. Daily micturition times, maximum voiding volume, visual analogue scale, O Leary-Sant IC questionnaire score, quality of life score and adverse reaction were monitored before and after treatment respectively. Results For A and B groups after 1 month perfusion, daily urination （14.5 ± 7.2, 13.4 ± 9.5）, maximum urine volume （185.7 ± 41.6, 190.8 ± 45.7）, visual analogue scale （3.7 ± 0.8, 3.4 ±0.6）, O＇Leary-Sant IC questionnaire score （14.7 ±4.9, 13.9 ± 5.9）, and quality of life score （1.8 ± 0.8, 1.7 ±0.9） were all improved significantly, compared to pre-treatment. For A and B groups after 6 months perfusion, daily urination （15.43 ± 6.7, 14.5 ± 7.8）, maxi- mum urine volume （195.8 ± 44.5, 201.7 ± 48.3）, visual analogue scale （3.9 ± 0.8, 3.6 ± 0.7）, O＇Leary-Sant IC questionnaire score （16.2 ±4.4, 15.5 ±5.6）, and quality of life score （2.3 ± 1.1, 2.1 ±1.3） were also improved sig- nificantly. But there were no significant differences in the degree of change of these indexes between two groups. There were 7 cases of bladder irritation and 4 cases of hematuria in group A, 3 cases of bladder irritation and 1 case of hematuria in group B. Conclusion Xiaozhiling intravesical treatment of PBS/IC is safe and effective. Its effect is equivalent to sodium hyaluronate.

关 键 词：膀胱疼痛综合征 间质性膀胱炎 消痔灵 透明质酸钠 膀胱灌注 

分 类 号：R694.3[医药卫生—泌尿科学]